O-2694
From Wikipedia, the free encyclopedia
O-2694
|
|
Systematic (IUPAC) name | |
[(6aR,10aR)-6,6,9-trimethyl-3-(2-methyl-7-morpholin-4-yl-7-oxoheptan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-yl] 4-(di(propan-2-yl)amino)butanoate | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C38H60N2O5 |
Mol. mass | 624.891 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
O-2694 is a drug which is a cannabinoid derivative. It has analgesic effects and is used in scientific research. Unlike most cannabinoids discovered to date, it is highly water soluble, which gives it considerable advantages over many related drugs. It has high affinity for both CB1 and CB2 receptors, with Ki values of 3.7nM at CB1 and 2.8nM at CB2. However it has complex pharmacokinetics as most of the administered dose is metabolised by hydrolysis of the ester link to the water-insoluble compound O-2372, thus producing a biphasic effects profile which is less suitable for research purposes than the related compound O-2545.[1]
[edit] References
- ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK. Pharmacological characterization of novel water-soluble cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1230-9. PMID 16757541
|